Theonie Anastassiadis
Oprichter bij Flagship Labs 89, Inc.
Profiel
Ms. Theonie Anastassiadis is a Chief Innovation Officer at Alltrna, a President at Prologue Medicines, Inc. and a Principal at Flagship Pioneering.
She received her undergraduate degree from Haverford College.
Actieve functies van Theonie Anastassiadis
| Bedrijven | Functie | Begin |
|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Analist | - |
Alltrna
 Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Oprichter | - |
| Flagship Labs 89, Inc. | Oprichter | - |
Opleiding van Theonie Anastassiadis
| Haverford College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Alltrna
Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Health Technology |
| Flagship Labs 89, Inc. | Health Technology |
